Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 169–192 of 328
Korsana emerges with $175m to combat neurodegenerative diseases
Korsana Biosciences has secured $175 million to develop KRSA-028, a monoclonal antibody for Alzheimer's disease that uses transferrin receptor-based shuttle technology to cross the blood-brain barrier more effectively than existing therapies. The approach addresses a fundamental delivery limitation in treating neurodegenerative diseases, with Phase 1 data expected in mid-2027.
Liver Drug Works Before Weight Loss Begins
Zabopegdutide demonstrates measurable improvements in liver fat, stiffness, and fibrosis within 12 weeks—improvements that occur independently of significant weight loss. This suggests the drug may act directly on hepatic tissue rather than working solely through weight reduction, potentially redefining therapeutic success in metabolic liver disease beyond the weight-loss-first paradigm.
Brain endothelial cell-derived extracellular vesicles (c-BEEVs) as a promising biomarker for brain vascular pathology and cognitive decline
Brain endothelial cell-derived extracellular vesicles (c-BEEVs) detected in cerebrospinal fluid serve as a measurable biomarker for vascular dysfunction affecting the brain and cognitive decline. This discovery enables earlier detection of neurovascular pathology before symptomatic cognitive loss.
Vertex moves toward FDA filing for chronic kidney disease drug
Vertex Pharmaceuticals reported Phase 3 trial results showing povetacicept reduced proteinuria by 52% in IgA nephropathy patients, compared to 4.3% in placebo groups, with an FDA filing planned by March. This represents a shift toward upstream immune intervention in kidney disease, addressing the autoimmune dysfunction driving tissue damage rather than managing symptoms alone.
Alnylam advances diabetes candidate ALN-4324 into Phase 2
Alnylam has advanced ALN-4324, an RNAi therapeutic targeting GRB14, into Phase 2 trials for Type 2 diabetes. The candidate is designed to improve whole-body insulin sensitivity through a single subcutaneous injection, representing a potential therapeutic approach to a primary metabolic dysfunction underlying age-related disease progression.
MBX Biosciences reports 2025 results and advances endocrine pipeline
MBX Biosciences advanced its endocrine and metabolic pipeline with a successful FDA End-of-Phase 2 meeting for canvuparatide in chronic hypoparathyroidism, positioning a Phase 3 trial for 2026. The company's funding runway extends to 2029, supporting multiple programs targeting metabolic dysfunction and hormone regulation.
Masitinib extends ALS survival to 42%, doubles registry benchmarks
AB Science's masitinib combined with riluzole demonstrated a 42.3% five-year survival rate in ALS patients, with 52.9% among those without baseline functional loss. These outcomes substantially exceed historical registry benchmarks of 7-27.8%, suggesting a meaningful therapeutic advance for a rapidly progressive neurodegenerative condition.
Troculeucel may boost cognition, new Alzheimer’s data shows
NKGen Biotech's Troculeucel, a patient-derived natural killer cell therapy, shows early Phase 1 signals of cognitive improvement in moderate Alzheimer's disease, with reduced blood markers of brain inflammation correlating with enhanced memory and thinking performance. This represents a mechanistic shift from symptom management toward mobilizing endogenous immune defenses to address disease progression.
Galimedix touts lower-dose oral Alzheimer’s drug
Galimedix presented preclinical data on a prodrug formulation of its oral Alzheimer's candidate that achieves higher systemic drug exposure at lower doses by improving absorption efficiency. The advancement addresses a critical practical constraint in neurodegenerative disease treatment: long-term medication adherence and tolerability.
Sustained dopaminergic delivery without skin toxicity in Parkinson's
Serina Therapeutics has developed a synthetic polymer platform (POZ) enabling precise, sustained drug delivery via subcutaneous injection, with early evidence suggesting its dopaminergic candidate SER-252 can maintain continuous stimulation in Parkinson's disease without localized adverse effects. This represents advancement in delivery technology that addresses both efficacy and tolerability in neurodegenerative disease management.
Celularity inks $35m deal for longevity push
Celularity secured $35 million in non-dilutive funding through a licensing agreement for its placental biomaterials portfolio, allowing the company to refocus resources on therapies targeting fundamental aging mechanisms while maintaining manufacturing and royalty streams. This capital structure reflects a strategic shift within regenerative medicine toward specialization in aging biology rather than symptomatic disease treatment.
Final patient out in AlzeCure’s study on Alzheimer’s
AlzeCure Pharma completed Phase Ib dosing of ACD856, demonstrating a wider-than-expected therapeutic window and safety profile across repeated higher doses. The completion positions the compound for Phase II trials and exploration across multiple neurological indications beyond Alzheimer's disease.
Cellular Senescence and Senotherapeutics: The Expert Roundup
Cellular senescence—the accumulation of cells that cease dividing but resist death—has emerged as a primary target in longevity medicine due to evidence that clearing these cells extends healthspan and can address root causes of age-related disease. Senotherapeutics, including senolytics and senomorphics, are transitioning from preclinical studies to clinical trials, though significant challenges in biomarker standardization, cellular heterogeneity, and clinical efficacy remain.
Senolytic Timing Matters: Sustained Clearance Outperforms Pulse Dosing
Senolytic treatment with dasatinib and quercetin in aged mice produced measurable remodeling across immune, fibrotic, and metabolic pathways, with sustained intervention showing greater efficacy than short-term exposure. This work maps the molecular cascades underlying senolytic action and establishes timing as a critical variable in cellular rejuvenation.
Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming
Senotherapeutics—strategies that eliminate or reprogram senescent cells—represent a shift from broad-spectrum senolytic approaches toward precision interventions that target specific cell types and contexts. This progression directly addresses a fundamental mechanism of aging, offering potential to extend healthspan by restoring cellular function rather than relying solely on senescent cell elimination.
Senescent cell clearance extends lifespan 70% in aged models
Immorta Bio's combined senolytic immunotherapy and regenerative cellular platform produced over 70% lifespan extension in aged animal models, alongside improvements in organ function, tissue repair, and markers of cellular recovery. The finding demonstrates that simultaneous clearance of senescent cells and activation of regenerative capacity can produce measurable gains in both lifespan and healthspan across multiple physiological domains.
Senescent Cell Clearance Unlocks Regenerative Therapy Efficacy
A preclinical study combining senescent cell clearance with stem cell-based regenerative therapy produced 70% lifespan extension in aged models, substantially outperforming either approach alone. The finding reinforces that addressing aging requires simultaneous intervention across multiple biological pathways rather than single-target strategies.
Senescent cells drive aging inflammation
Cellular senescence—the accumulation of non-dividing cells that secrete inflammatory factors—drives age-related decline in multiple organ systems. Understanding how senescent cells compromise tissue function and identifying interventions that clear or manage their activity offers a direct path to extending both healthspan and lifespan.
NAD+ webinar set to examine delivery dilemma
NAD+ delivery methods—pills, injections, and pens—are receiving increased clinical scrutiny as the molecule transitions from niche longevity therapy to mainstream wellness category. The effectiveness of NAD+ depends less on the molecule itself than on bioavailability, formulation quality, and whether patients maintain consistent use.
Senolytic Clearance Restores Lung Immunity in Aging
A correction to published research on senolytics—drugs that selectively eliminate senescent cells—clarifies dosing and outcome measures in aged mice infected with influenza. The findings support senolytics as a tool for reducing both acute and chronic inflammatory responses in aged lungs, with direct relevance to infection susceptibility in aging.
Senescent cell clearance and stem cell therapy extend lifespan 70%
A dual-therapy approach combining senescent cell clearance with mesenchymal stem cell restoration produced a 70% lifespan extension in mice, accompanied by sustained improvements in physiological function. This preclinical result demonstrates that coordinated interventions targeting cellular aging and tissue regeneration can produce measurable longevity gains.
NAD+ IV Therapy Supports Cellular Energy and DNA Repair
Aeon Clinic in Dubai offers intravenous NAD+ supplementation and micronutrient delivery, claiming support for metabolic function, DNA repair, and cognitive clarity through direct bloodstream administration. The clinical model emphasizes physician oversight and personalized protocols as distinguishing factors in the premium wellness space.
Restore Hyper Wellness kicks off NAD Month to educate on IV, IM therapies
Restore Hyper Wellness is promoting NAD supplementation through IV and intramuscular delivery formats, capitalizing on significant year-over-year increases in consumer search interest for NAD-related therapies. The initiative positions NAD precursors and direct NAD administration as tools for cellular energy optimization, though clinical evidence supporting broad longevity claims remains limited.
Decreased Glucose Metabolism and Declined Chaperones Are Unique Features Required for the Survival of Senescent Fibroblasts and Pyruvate Dehydrogenase Is a Potent Senolytic Target
Senescent fibroblasts depend on reduced glucose metabolism and maintained chaperone proteins for survival. Inhibiting pyruvate dehydrogenase selectively eliminates senescent cells, including therapy-induced senescent cancer cells, with synergistic enhancement when combined with chaperone inhibition.